Stockscreener 앱 받기
1.1245
3.42%
-0.0455
전일 마감가:
$1.17
열려 있는:
$1.19
하루 거래량:
223.81K
Relative Volume:
0.75
시가총액:
$71.51M
수익:
$3.67M
순이익/손실:
$-13.83M
주가수익비율:
-4.0161
EPS:
-0.28
순현금흐름:
$-10.79M
1주 성능:
-7.38%
1개월 성능:
-0.88%
6개월 성능:
+43.04%
1년 성능:
-5.04%
1일 변동 폭
$1.1103
$1.1986
1주일 범위
$1.1103
$1.34
52주 변동 폭
$0.48
$1.66
Icecure Medical Ltd Stock (ICCM) Company Profile
ICCM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ICCM
Icecure Medical Ltd
|
1.12 | 71.51M | 3.67M | -13.83M | -10.79M | -0.28 |
|
ABT
Abbott Laboratories
|
132.30 | 224.65B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
104.57 | 151.13B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
382.57 | 139.34B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
83.44 | 108.80B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
75.41 | 44.25B | 5.54B | 4.18B | 259.90M | 7.00 |
Icecure Medical Ltd 주식(ICCM)의 최신 뉴스
IceCure Medical Ltd (NASDAQ:ICCM) Shares Acquired by Geode Capital Management LLC - Defense World
IceCure Medical Takes Next Major Initiative as it Prepares to Accelerate the Commercialization of ProSense in U.S. and Canada: Appoints VP of Sales, North America - Barchart.com
IceCure Medical reports on FDA meeting for ProSense Cryoablation - TipRanks
ICCM Advances ProSense Approval with FDA Interface | ICCM Stock News - GuruFocus
IceCure Announces Positive FDA Development: Understanding on Pat - GuruFocus
FDA Clears Path for Revolutionary Breast Cancer Treatment: ProSense Set to Transform Care for 46,000 Patients - Stock Titan
IceCure Exhibits ProSense® & Sponsors Breast Cryoablation Courses at the Society of Breast Imaging Symposium - GuruFocus
IceCure Receives Notice of Patent Allowance in Japan for a Novel Cryogenic Pump for its Next-Generation Cryoablation Systems - marketscreener.com
IceCure's ProSense® Featured at European Conference on Interventional Oncology with an Emphasis on Breast Cancer Cryoablation - StreetInsider
IceCure's ProSense® Featured at European Conference on Interventional Oncology with an Emphasis on Breast Cancer Cryoablation | ICCM Stock News - GuruFocus
Clinical Trial Reveals Revolutionary Breast Cancer Treatment: ProSense Shows 94% Success, Zero Complications - Stock Titan
IceCure Medical (NASDAQ:ICCM) Shares Down 3.1% – Time to Sell? - Defense World
IceCure Medical Announces Special Shareholder Meeting for May 2025 - TipRanks
FY2027 EPS Estimates for IceCure Medical Reduced by Analyst - Defense World
IceCure Medical (NASDAQ:ICCM) Earns Buy Rating from HC Wainwright - Defense World
IceCure Medical Stock Dips Despite Positive ICESECRET Study Results - Zacks Investment Research
Genomic Differences Impact Real World Use of Elacestrant in Breast Cancer - Targeted Oncology
H.C. Wainwright maintains Buy on IceCure Medical with $2.50 target By Investing.com - Investing.com India
IceCure Medical Ltd (NASDAQ:ICCM) Q4 2024 Earnings Call Transcript - Insider Monkey
H.C. Wainwright maintains Buy on IceCure Medical with $2.50 target - Investing.com
IceCure Medical Reports Growth and Awaits FDA Decision - TipRanks
IceCure Medical Ltd’s Earnings Call: Growth Amidst Challenges - TipRanks
IceCure Medical to Report 2024 Full Year Financial & Operational Results on March 27, 2025 - PR Newswire
Earnings call transcript: Icecure Medical’s Q4 2024 sees growth in sales but wider losses By Investing.com - Investing.com South Africa
Earnings call transcript: Icecure Medical’s Q4 2024 sees growth in sales but wider losses - Investing.com
IceCure Medical Reports 2024 Financial Results: 42% Growth in ProSense® Cryoablation Sales in North America - StreetInsider.com
Earnings Outlook For Icecure Medical - Benzinga
IceCure Medical aims to bring cold cancer treatment to Vietnam - Mugglehead Magazine
IceCure Medical (ICCM) Projected to Post Earnings on Thursday - Defense World
IceCure's ICESECRET Kidney Cancer Cryoablation Study Interim Results Presented at European Association of Urology Conference in Spain: 88.7% Recurrence-Free Rate - The Malaysian Reserve
IceCure's ICESECRET Kidney Cancer Cryoablation Study Interim Res - GuruFocus
IceCure reports high efficacy in kidney tumor cryoablation study By Investing.com - Investing.com South Africa
IceCure reports high efficacy in kidney tumor cryoablation study - Investing.com India
IceCure Medical Earnings: Cryoablation Pioneer Reports 2024 Results March 27 - Stock Titan
IceCure Reports Updated Timeline and Progress with FDA Regarding Marketing Authorization for ProSense® Cryoablation in Early-Stage Breast Cancer - The Malaysian Reserve
Targeting ESR1 Mutations in Breast Cancer With Novel Therapies - Targeted Oncology
IceCure stock tumbles after update on ProSense (ICCM:NASDAQ) - Seeking Alpha
IceCure Medical Ltd. Reports Updated Timeline and Progress with FDA Regarding Marketing Authorization for ProSense®? Cryoablation in Early-Stage Breast Cancer - Marketscreener.com
IceCure Medical Expects FDA Decision on ProSense After Q1 -March 20, 2025 at 09:20 am EDT - Marketscreener.com
IceCure nears FDA decision on breast cancer treatment - Investing.com
IceCure nears FDA decision on breast cancer treatment By Investing.com - Investing.com UK
IceCure's ProSense® Cryoablation Featured in Six Studies Presented at St. Gallen International Breast Cancer Conference - PR Newswire
Icecure Medical Ltd (ICCM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
10.27%
0.08%
자본화:
|
볼륨(24시간):